Blood Test for Brain Proteins After Temporary Barrier Opening Using Electrical Fields in Adults Undergoing Spine Tumor Surgery

What this Trial Is About

Researchers are studying patients with spinal tumors who are undergoing spine surgery to find new central nervous system CNS biomarkers. These biomarkers are measured in blood after temporarily opening the blood-arachnoid barrier using a technique called Barrier Disrupting Fields BDF. This feasibility study aims to compare CNS biomarker levels in blood and cerebrospinal fluid CSF during surgery and monitor safety events related to the BDF procedure. Patients who need intradural tumor resection spinal surgery with intraoperative neuromonitoring will participate. During surgery, electrodes are attached to the patients head after anesthesia, and blood samples are taken before and after the BDF procedure. The BDF uses low pulsed electric fields to transiently open the barrier protecting the brain. Surgery then continues as usual, with a CSF sample collected when the dura is opened to compare with blood biomarkers. Participants will be involved over about 24 months with assessments including blood and CSF sampling during surgery. Researchers will measure changes in blood CNS biomarker concentrations after BDF compared to CSF levels. Safety will be monitored by recording any adverse events related to BDF using standard grading criteria. The study seeks to advance blood-based methods for detecting brain proteins in patients undergoing spine surgery.

Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery